AC Immune Receives FDA Fast Track Designation for ACI-7104 in Parkinson’s
LAUSANNE, Switzerland, August 11, 2026 AC Immune SA announced that the U.S. Food and Drug Administration (FDA) has granted...
immunogenicity
Advertisement
Delonix Bioworks Doses First Participant in DX-104 Trial
SHANGHAI, China, July 13, 2026 Delonix Bioworks, a clinical-stage biotechnology company specializing in genetically engineered bacterial vaccines, has announced...
Vaxcyte Doses First Participant in Phase 1 Trial of VAX-A1 for Group A Strep Prevention
SAN CARLOS, Calif., June 2, 2026 Vaxcyte, Inc. announced that the first participant has been dosed in a Phase...
GC Biopharma’s Recombinant Anthrax Vaccine Shows Strong Phase 2 Safety and Efficacy Results
Yongin, South Korea — November 3, 2025 GC Biopharma has announced promising Phase 2 clinical trial results for its...
Advertisement
